Navigation Links
Pharmion and MethylGene Announce U.S. Orphan Drug Designation Granted for MGCD0103 for the Treatment of Acute Myelogenous Leukemia
Date:2/14/2008

is characterized by the rapid proliferation (growth) of abnormal white blood cells. These cells are unable to perform their regular functions and eventually crowd out healthy red and white blood cells. Leukemia cells can also spread to other parts of the body. People afflicted with AML are susceptible to increased risk of infections, anemia and bleeding.

AML is the one of the most common forms of leukemia and occurs most often in older adults -- the average age being 65. The American Cancer Society estimates that 13,410 new cases and 8,990 deaths occurred in the United States in 2007.

Although several risk factors for AML have been identified, the specific cause of AML remains unclear. AML is a potentially curable disease; but only a minority of patients are cured with current therapies. Current treatments for AML include chemotherapy, blood transfusions and stem cell transplants.

About Pharmion

Pharmion is a leading global oncology company focused on acquiring, developing and commercializing innovative products for the treatment of hematology and oncology patients in the U.S., Europe and additional international markets. Pharmion has a number of products on the market including the world's first approved epigenetic drug, Vidaza(R), a DNA demethylating agent. For additional information about Pharmion, please visit the company's website at http://www.pharmion.com.

About MethylGene

MethylGene Inc. (TSX: MYG) is a publicly-traded biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for cancer. The Company's lead product, MGCD0103, is an oral isotype-selective HDAC inhibitor presently in multiple clinical trials for solid tumors and hematological malignancies, including Phase II monotherapy and Phase I and Phase II combination trials with Vidaza(R), Gemzar(R) and Taxotere(R). MGCD265 is an oral kinase inhibitor targeting t
'/>"/>

SOURCE Pharmion Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Acute Myelogenous Leukemia
2. Thalidomide Pharmion(R) Receives Positive Opinion for Treatment of First-line Multiple Myeloma from European Medicines Agency
3. Pharmion Submits European Marketing Authorization Application (MAA) for Vidaza(R) in Patients with Higher-Risk Myelodysplastic Syndromes (MDS)
4. Pharmion and MethylGene Start Phase 2 Combination Clinical Trial With MGCD0103 and Vidaza(R) in Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
5. Pharmions Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
6. Pharmion and MethylGene Report Preliminary MGCD0103 Clinical Data at the 2007 AACR-NCI-EORTC International Conference
7. Pharmion Initiates Pivotal Phase 3 Study of Amrubicin in Small Cell Lung Cancer
8. Pharmion and MethylGene Initiate Phase One Combination Clinical Trial with MGCD0103 and Taxotere(R) in Patients with Solid Tumors
9. Pharmion and MethylGene Announce U.S. Orphan Drug Designation Granted for MGCD0103 for the Treatment of Hodgkins Lymphoma
10. Raven Announces Completion of Enrollment in the Phase 1/2a Clinical Trial of RAV12 Therapeutic Antibody for the Treatment of Adenocarcinomas
11. Watson Announces Silodosin NDA Accepted for Filing by FDA for the Treatment of Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/19/2014)... Shire plc (LSE: SHP, NASDAQ: SHPG ) announces that ... the Board of Directors of his decision to step down from ... of Severn Trent plc.  James will leave Shire at the end ... a new CFO immediately. Flemming Ornskov, Shire,s Chief Executive ... high-quality finance team at Shire. We are very grateful to him ...
(Date:10/17/2014)... Oct. 17, 2014 With the recent ... function has come across several challenges in creating ... managing globalization.  The Medical ... dedicated to providing benchmarking and best practices across ... is a service composed of three stages: 1) ...
(Date:10/17/2014)... Research ... addition of the  "China Interventional Cardiovascular Device ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) The ... China impacted by accelerated aging ... dietary habit, way of working and other ...
Breaking Medicine Technology:Interim Chief Financial Officer James Bowling to Step Down 2Interim Chief Financial Officer James Bowling to Step Down 3Interim Chief Financial Officer James Bowling to Step Down 4Early Key Findings from the Medical Affairs Consortium Research 2China Interventional Cardiovascular Device Industry Report 2014-2017 2China Interventional Cardiovascular Device Industry Report 2014-2017 3
... The oncology therapeutic area continues to be an ... as next generation oncology therapies find success in a ... success, organizations in the oncology therapeutic area are facing ... the factors that play the biggest role in the ...
... Caliper Life Sciences, Inc. (NASDAQ: CALP ... second quarter financial results at 5:00 pm Eastern (2:00 ... President and Chief Executive Officer, and Peter McAree, Chief ... operational and financial results and the company,s outlook for ...
Cached Medicine Technology:Success Factors and Failure Points for Oncology New Product Launches 2Caliper Life Sciences' Second Quarter Results Conference Call Notice 2
(Date:10/19/2014)... 20, 2014 The leading review ... http://www.top10bestseohosting.com/go/iPage/ ) and GreenGeeks are the best Dedicated ... for those who want to buy high quality ... , The IT manager of Top10BestSEOHosting.com says, “We ... recommended suppliers for everyone. A lot of the ...
(Date:10/19/2014)... Dallas, Texas (PRWEB) October 20, 2014 ... therapeutic development for Partial Seizure, complete with comparative ... target, mechanism of action (MoA), route of administration ... and featured news and press releases. It also ... for Partial Seizure and special features on late-stage ...
(Date:10/19/2014)... 20, 2014 Recently, Fancyflyingfox.com, an innovative ... clothes, has announced its latest designs of 2014 ... the new elegant outfits are offered with big discounts, ... order before October 30 can enjoy this special offer. ... marketing strategies, it has become one of the leading ...
(Date:10/19/2014)... Stephen T. Greenberg, M.D., with offices in Woodbury, Southampton and ... as one of Long Island’s best cosmetic surgeons. In ... the best provider for Botox injections. Glisten, his Skin & ... best Laser Treatment center on Long Island.* , The voting ... the contest once per day, per IP address. , Stephen ...
(Date:10/19/2014)... 2014 – The U.S. Government has initiated a ... disease by 2025. However, a workgroup of nearly ... milestones in the U.S. Government,s National Plan to ... increased in scale, and adequately funded in order ... proposals by the workgroup to enlarge and strengthen ...
Breaking Medicine News(10 mins):Health News:Top10BestSEOHosting.com Considers iPage And GreenGeeks As The Best Dedicated Server Hosting Suppliers 2Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 2Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 3Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 4Health News:Fancyflyingfox.com Updates Its Website With New Mother Of The Bride Dresses For 2014 2Health News:Dr. Stephen T. Greenberg – Nominated for the 10th Consecutive Year for One of Long Island’s Best Cosmetic Surgeons for 2015 by the Long Island Press 2Health News:Scientists say national Alzheimer's plan milestones must be strengthened to meet goal by 2025 2Health News:Scientists say national Alzheimer's plan milestones must be strengthened to meet goal by 2025 3Health News:Scientists say national Alzheimer's plan milestones must be strengthened to meet goal by 2025 4Health News:Scientists say national Alzheimer's plan milestones must be strengthened to meet goal by 2025 5Health News:Scientists say national Alzheimer's plan milestones must be strengthened to meet goal by 2025 6
... Reinberg HealthDay Reporter , MONDAY, Nov. 14 (HealthDay ... needed medications if they,re free, U.S. researchers find. Less ... their prescribed medications, which increases hospitalizations, deaths and costs to ... if eliminating the co-pay fee might entice more patients to ...
... may be making premature predictions about which patients are ... even withdrawing care -- before the window in which ... likely to wake up, according to two new studies ... of Pennsylvania. The research helps to better define the ...
... Women with the deadliest and rarest form of breast cancer ... were severely limited, thanks to a new discovery by George ... called "inflammatory breast cancer," kills about half the women who ... mere 18 months after diagnosis. About 10,000 women are diagnosed ...
... Scientists presented new research today demonstrating the impact life ... examine how such environmental information can be transmitted from ... as epigenetics. This new knowledge could ultimately improve understanding ... how a parent,s exposure to drugs, alcohol, and stress ...
... of therapeutic hypothermia and delay in return of spontaneous ... measurable blood pressure, were both associated with poor neurologic ... study being presented Nov. 14 at the at the ... Also, caregivers who have an appropriate understanding of the ...
... Reporter , SUNDAY, Nov. 13 (HealthDay News) -- Tragic stories ... on the playing field due to an undetected heart problem. ... aimed at helping doctors and coaches detect these problems early ... suggests that only a small percentage of physicians are heeding ...
Cached Medicine News:Health News:More Heart Attack Patients Take Meds When They Are Free 2Health News:More Heart Attack Patients Take Meds When They Are Free 3Health News:Withdrawal of care may occur too soon in cardiac arrest patients who receive hypothermia treatment 2Health News:Withdrawal of care may occur too soon in cardiac arrest patients who receive hypothermia treatment 3Health News:George Mason University research gives hope to women with deadliest breast cancer 2Health News:George Mason University research gives hope to women with deadliest breast cancer 3Health News:Nature and nurture work together to shape the brain 2Health News:Better understanding of neurologic defects improves post-cardiac-arrest discharge 2Health News:Too Few Doctors Screen Young Athletes for Hidden Heart Trouble 2Health News:Too Few Doctors Screen Young Athletes for Hidden Heart Trouble 3
... of guiding introducers includes Swartz™ Series, ... piece steerable, all designed for the ... varying curves and longer sheath lengths ... Jude Medical guiding introducers are designed ...
Lumenis 1000 Integrated Slit Lamp Fully-integrated biomicroscope slit lamp laser delivery system, complete with built-in LaserLink, parallel optics, magnification changer, micromanipulator and multi...
Novus 30001 A fully-integrated and powerful 532 nm Operating Room Photocoagulator with reliable DPSS technology and simplified operation using a touch screen interface and remote control....
... Selecta Trio The pinnacle ... Nd:YAG, diode-pumped solid-state (DPSS) 532 ... laser (SLT) and offering maximum ... The first and only Nd:YAG, ...
Medicine Products: